 FREMONT, Calif., May 26, 2021 GLOBE NEWSWIRE -- Zosano Pharma Corporation NASDAQ:ZSAN, a clinical-stage biopharmaceutical company, today announced that an article titled, Long Term Safety, Tolerability, and Efficacy of Intracutaneous Zolmitriptan M207 in the Acute Treatment of Migraine was published in The Journal of Headache and Pain . This open-label, multicenter observational study was designed to evaluate the safety and efficacy of the repeated use of QtryptaTM in adults with migraine who had historically experienced at least 2 migraine attacks per month. The tolerability and efficacy results in this long-term study were consistent with the results observed in the Phase 23 ZOTRIP study. 